Cross Country Healthcares Inc Dossier
|
SectorHealth Care IndustryHealth Care Services Beta (adjusted)0.63 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $13.25Price as of 20 Jul 2026 Data confidenceNot applicable Market Cap $428.1M Enterprise Value $322.5M Shares Outstanding 31.6M diluted Moat Rating None All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Cross Country Healthcare (CCRN) is currently in a definitive agreement to be acquired by private equity firm Knox Lane for $13.25 per share in an all-cash transaction valued at approximately $437 million. This transaction follows a previously terminated merger agreement with Aya Healthcare in late 2025 due to regulatory pushback. Given that the stock is trading very close to the acquisition price of $13.25 (with less than a 1% spread), there is limited upside for public investors. The transaction is expected to close in the third quarter of 2026, subject to stockholder and regulatory approvals. Consequently, a Hold rating is recommended as the stock is expected to remain anchored to the deal price until completion. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$10.00 Mean target$12.44 High · most bullish analyst$13.25 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $10.00 The merger with Knox Lane fails to close due to unexpected regulatory challenges or failure to obtain stockholder approval. In this scenario, the stock would likely fall back to its standalone fundamental value, which is pressured by declining volumes in nurse and physician staffing. Base CaseCentral scenario $13.25 The stock continues to trade in a tight range near the $13.25 acquisition price as the market awaits the stockholder vote on July 16, 2026, and regulatory clearances. The deal is highly likely to close in Q3 2026 given the lack of significant overlapping market concentration compared to the prior Aya Healthcare transaction. Bull CaseUpside scenario $13.25 The transaction closes smoothly in Q3 2026, delivering the full $13.25 per share cash consideration to stockholders. This represents a successful exit and a significant premium over the pre-announcement trading levels. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |